Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 2/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4625372 | 1.00 | TTR (0.43) | TTRTDP1KDM1ATSHRLMNA | |
| Dioxane SCHEMBL10324821 | 0.91 | CA2 (0.35) | TTRTDP1 | |
| Dioxane SCHEMBL8149387 | 0.91 | CA2 (0.35) | TTRTDP1 | |
| Dioxane SCHEMBL3104036 | 0.91 | CA2 (0.35) | TTRTDP1 | |
| SCHEMBL3743823 | 0.87 | — | — | |
| Tetrahydrofuran SCHEMBL2361115 | 0.87 | ALDH1A1 (0.50) | TDP1KDM1A | |
| Dioxane SCHEMBL299082 | 0.86 | TDP1 (0.34) | TTRTDP1TSHRLMNAGAA | |
| SCHEMBL7703561 | 0.84 | ALDH1A1 (0.47) | TDP1 | |
| SCHEMBL6814772 | 0.84 | ALDH1A1 (0.47) | TDP1 | |
| Tetrahydrofuran SCHEMBL5235661 | 0.84 | ALDH1A1 (0.47) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101778852-A | Bisamine zinc base | UNIV MUENCHEN L MAXIMILIANS | 2010-07-14 | — | — | CN | claimed |
| US-6403776-B1 | TREATING ANTIBIOTIC COMPOUND WITH NUCLEOPHILE TO CLEAVE PROTECTING GROUP FROM HYDROXYL GROUP | PFIZER INC. | 2002-06-11 | — | — | US | claimed |
| US-20020016512-A1 | Heterogeneously catalyzed process for cross coupling aryl chlorides with aryl boronic acids | SUN YONGKUI (US) | 2002-02-07 | — | — | US | claimed |
| US-6290926-B1 | CATALYSIS OF CARBON MONOXIDE CONVERSION VIA THE WATER-GAS SHIFT REACTION | STUDIENGESELLSCHAFT KOHLE MBH (DE) | 2001-09-18 | — | — | US | claimed |
| US-4900477-A | Novel intermediates and an improved process for producing the compound (3β,5α)-3-hydroxycholest-8(14)-en-15-one | AMERICAN CYANAMID COMPANY (US) | 1990-02-13 | — | — | US | claimed |
| EP-4263539-A1 | 6-6 OR 5-6 FUSED BICYCLIC COMPOUNDS COMPRISING A PYRI(MI)DINE RING USEFUL IN THE TREATMENT OF INFECTIOUS DISEASES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE - INSERM (FR) | 2023-10-25 | — | — | EP | disclosed |
| US-11518756-B2 | Arylation method | UMICORE AG & CO. KG (DE) | 2022-12-06 | — | — | US | disclosed |
| WO-2022129376-A1 | 6-6 OR 5-6 FUSED BICYCLIC COMPOUNDS COMPRISING A PYRI(MI)DINE RING USEFUL IN THE|TREATMENT OF INFECTIOUS DISEASES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2022-06-23 | — | — | WO | disclosed |
| CN-114430680-A | Novel anticancer drug FL118 formulation and combination immunotherapy thereof for treating human cancers | 坎格特生物技术制药有限责任公司 | 2022-05-03 | — | — | CN | disclosed |
| US-20200031803-A1 | ARYLATION METHOD | UMICORE AG & CO. KG (DE) | 2020-01-30 | — | — | US | disclosed |
| US-10476073-B2 | Production process for carbon-coated silicon material | KABUSHIKI KAISHA TOYOTA JIDOSHOKKI (JP) | 2019-11-12 | — | — | US | disclosed |
| CN-109219518-A | Multilayer film | 株式会社可乐丽 | 2019-01-15 | — | — | CN | disclosed |
| EP-0015079-B1 | HALOGENATING COMPOUNDS AND A PROCESS FOR THEIR PRODUCTION | ELI LILLY AND COMPANY (US) | 1987-09-09 | — | — | EP | disclosed |
| US-4321413-A | IN THE PRESENSE OF ANIONIC EXCHANGE RESIN CATALYSTS | TEXACO INC. (US) | 1982-03-23 | — | — | US | disclosed |
| EP-0015079-A1 | Halogenating compounds and a process for their production | ELI LILLY AND COMPANY (US) | 1980-09-03 | — | — | EP | disclosed |
| US-4156723-A | HYPOTENSIVE | E. R. SQUIBB & SONS, INC. (US) | 1979-05-29 | — | — | US | disclosed |
| US-4144249-A | 2,2,6,6-TETRAMETHYL-BENZOBISDIOXOLE, USEFUL IN PERFUMES | S.A. TEXACO BELGIUM N.V. (BE) | 1979-03-13 | — | — | US | disclosed |
| EP-0000800-A1 | Selective N-protection of aminoglycosides and novel, selectively protected aminoglycoside intermediates | Technobiotic Ltd. (CH) | 1979-02-21 | — | — | EP | disclosed |
| US-4123437-A | REACTING A HYDRAZINE WITH AN ALKOXYCARBONYL ISOTHIOCYANATE, CYCLIZATION | CIBA-GEIGY CORPORATION (US) | 1978-10-31 | — | — | US | disclosed |
| US-4092331-A | FROM A POLYHYDRIC PHENOL CONTAINING TWO PAIR ORTHO HYDROXY GROUPS AND A KETONE OR ACETAL, LEWIS ACID CATALYST | S.A. TEXACO BELGIUM N.V. (BE) | 1978-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016512-A1 | Heterogeneously catalyzed process for cross coupling aryl chlorides with aryl boronic acids | MAP2K6, AHR, MAP2K2 | TTR 4301/4885TDP1 3913/4885KDM1A 2042/4885 |
| US-11518756-B2 | Arylation method | AHR, ARNT, CYP2B6 | TTR 1380/4885TDP1 3735/4885KDM1A 1804/4885 |
| US-20200031803-A1 | ARYLATION METHOD | AHR, ARNT, CYP2B6 | TTR 1380/4885TDP1 3735/4885KDM1A 1804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.